Objective: To study the expression status of caveolin-1, caveolin-2 and caveolin-3 in the epithelial and stromal compartments of conventional papillary thyroid carcinoma (PTC), diffuse sclerosing variant of papillary carcinoma (DSVPC) and anaplastic carcinoma (AC). Methods: Tissue microarrays were constructed from 70 PTC, 41 DSVPC and 12 AC, and immunohistochemical stains were performed with caveolin-1, caveolin-2, caveolin-3, cytokeratin, vimentin and E-cadherin. The expression status of these markers in the epithelial and stromal cells was evaluated, and the results were correlated with the clinicopathologic variables. Results: Epithelial caveolin-3 expression was absent in the majority of PTC and DSPVC, and was significantly increased in AC (p < 0.001). The stromal expression of caveolin-1, caveolin-2 and caveolin-3 increased in frequency from PTC to DSVPC to AC, and was significantly increased in the stroma of AC (p < 0.001). Cytokeratin and E-cadherin were more frequently negative in AC compared to PTC (p = 0.003) and DSVPC (p < 0.001), while vimentin was more frequently expressed in AC compared to PTC and DSVPC (both p < 0.001). Conclusion: Epithelial caveolin-3 expression is increased in AC compared to PTC and DSVPC, and this may be linked to the epithelial-mesenchymal transition process of AC. In addition, stromal caveolin-1, caveolin-2 and caveolin-3 expression was more frequent in AC compared to PTC and DSVPC, and the specific expression of caveolin-3 in the stroma of AC could suggest a possible role of myofibroblasts.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.